{
    "nctId": "NCT01194440",
    "briefTitle": "Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms",
    "officialTitle": "A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 63,
    "primaryOutcomeMeasure": "Number of Participants With Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)",
    "eligibilityCriteria": "Inclusion Criteria\n\n* Patients with histologically proven DCIS or stage I-III invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive by immunohistochemical staining who are considering aromatase inhibitor therapy; women may receive the AI on this study as initial adjuvant hormonal treatment or following tamoxifen; patients must have completed any adjuvant chemotherapy; patients may have received preoperative chemotherapy\n* Postmenopausal status, defined as: \\>= 60 years of age; or \\< 60 years of age and amenorrheic for \\>= 12 months prior to day 1 if intact uterus/ovaries; or \\< 60 years of age, and the last menstrual period 6-12 months prior to day 1, if intact uterus/ovaries and meets biochemical criteria for menopause (FSH and estradiol within institutional standards for postmenopausal status); or \\< 60 years of age, without a uterus, and meets biochemical criteria for menopause (FSH and estradiol within institutional standards for postmenopausal status); or \\< 60 years of age and history of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least 6 months; \\< 60 years of age and taking medication designed to suppress ovarian function and meets biochemical criteria for menopause (estradiol levels within institutional standards for postmenopausal status; women would have had to be taking the drug for at least 30 days prior to day 1)\n* ECOG performance status 0-2\n* Patient is aware of the nature of her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form\n\nExclusion Criteria\n\n* Concurrent use of hormone replacement therapy\n* Concurrent use of tamoxifen; patients taking tamoxifen must discontinue the drug prior to first dose of zoledronic acid\n* Concurrent use of other selective estrogen receptor modulator (SERM) such as raloxifene\n* Concurrent consumption of soy supplements; routine dietary consumption of soy containing foods will be permitted\n* Prior use of an aromatase inhibitor in any setting\n* Current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be eligible as long as the use was \\> 1 month ago for oral bisphosphonates and/or \\> 12 months ago for intravenous bisphosphonates, prior to starting study treatment\n* Moderate to severe renal impairment (serum creatinine greater than 2 mg/dL or creatinine clearance less than 50 mL/min)\n* Hypersensitivity to letrozole or zoledronic acid or any of its excipients\n* Concomitant treatment with oral or intravenous corticosteroids\n* Current active dental problems including infection or the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures\n* Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}